$17.71
1.61% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Aeglea BioTherapeutics Inc Stock price

$17.71
+2.78 18.62% 1M
-6.21 25.96% 6M
-5.57 23.93% YTD
-19.29 52.14% 1Y
-192.04 91.56% 5Y
-226.54 92.75% 10Y
-226.54 92.75% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.29 1.61%
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $504.04m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.21
Free Cash Flow (TTM) Free Cash Flow $-169.86m
Cash position $564.82m
P/E forward negative
Short interest 25.72%

Is Aeglea BioTherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Aeglea BioTherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Aeglea BioTherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
30% 30%
-
- Research and Development Expense 163 163
24% 24%
-
-209 -209
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -209 -209
16% 16%
-
Net Profit -208 -208
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aeglea BioTherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeglea BioTherapeutics Inc Stock News

Neutral
PRNewsWire
7 days ago
WALTHAM, Mass. , June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independe...
Neutral
PRNewsWire
16 days ago
WALTHAM, Mass. , May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate ...
Neutral
PRNewsWire
about one month ago
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or biannual dosing, and provides complete target engagement...
More Aeglea BioTherapeutics Inc News

Company Profile

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Head office United States
CEO Cameron Turtle
Employees 65
Founded 2013
Website spyre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today